Industry Leader
Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
-
Optimism For Life Sciences Growth Amid Policy Shifts In 2025
EY's Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.
-
Burn Out Or Busting Out
There is no clear metric for measuring a biopharmaceutical organization's energy. However, leaders that direct, create, and conserve energy can enhance employee wellbeing and improve business performance, explains Ron Cooper.
-
The Power of Putting People First in Driving Business Growth
Happy workers drive high performing businesses. Biopharma executive John Harlow shares five tips for adopting a people-first mindset and other strategies for meaningful engagement with colleagues.
-
Five Lessons For Creating The Drug Development Leaders Of Tomorrow
Inspiring and nurturing the drug development leaders of tomorrow throughout their school years, early work experiences, and their careers helps patients, companies, and society at large. AstraZeneca's Renee Iacona provides the how and why.
-
How Prioritizing OpEx Can Raise Sinking Biopharma Valuations
As investment in the life sciences industry decreases, young companies struggle to keep the lights on. Young companies may overcome these challenges by implementing operational excellence (OpEx) early on in drug development rather than waiting until manufacturing startup.
-
From Robotics To AI … Yesterday's Unknown Is Tomorrow's Promise
As part of my professional consulting and patient advocacy work in healthcare, I have learned about AI and seen first-hand the difference it is already making for countless patients and physicians around the world.
-
Why Founder CEOs Deliver In Bear Markets
Downturns like the current one highlight the need to move from an industry built for the next exit to one that’s built to benefit patients by prioritizing the best science and sustainable drug innovation.
-
How IT Can Drive Life Sciences Innovation
Here are three ways biotech companies and research universities can better balance IT demands with researchers’ needs.
-
Can We Accelerate Biosimilars Development Without Compromising Quality Or Safety?
What can we do to accelerate biosimilars’ path to market without compromising quality or safety? While clinical changes would likely take years, if not decades, to implement, innovations in CMC protocols may provide near-term solutions.
-
My Path From The Clinic, To Research, To Biotech Leadership
I never thought I would leave academia. However, “a knock” on my career door presented me with an opportunity to join a biotech company with cell-free DNA testing. I considered my options carefully, spoke with family and mentors, and made the leap earlier this year.
IN THIS MONTH'S ISSUE
- Gene Editing Versus Gene Therapy: Is There A Difference?
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Ensuring Diversity And Accessibility In Neurological Research
- A New Year's Resolution Suggestion For The FDA
- Pharma's Customer Engagement Evolution: Is Your Data Governance Keeping Pace?
BEYOND THE PRINTED PAGE
-
2023 Manufacturing And Supply Chain Outlook: Additional Insights12/16/2022
Additional executive responses to our 2023 manufacturing and supply chain outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 212/9/2022
Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 112/2/2022
Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.